Cabaletta Bio’s Rese-Cel Shows Early CAR-T Activity Without Lymphodepletion in Pemphigus Vulgaris

Company: Cabaletta Bio · Event Type: Peer-Reviewed Publication · Modality: Autologous CD19 CAR-T Cell Therapy · Product: Resecabtagene autoleucel (rese-cel) · Target Indication: Pemphigus Vulgaris · Publication Date: July 30, 2026 (Blood) Summary A peer-reviewed brief report in Blood, published online July 30, 2026 and…